Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDT
Company Participants
Christopher Stevo – Senior Vice President of Investor Relations & Competitive Intelligence
Richard Francis – President, CEO & Director
Eric Hughes – Executive VP of Global R&D and Chief Medical Officer
Eliyahu Kalif – Executive VP & CFO
Conference Call Participants
Jason Gerberry – BofA Securities, Research Division
Umer Raffat – Evercore ISI Institutional Equities, Research Division
Louise Chen – Scotiabank Global Banking and Markets, Research Division
Yuchen Ding – Jefferies LLC, Research Division
David Amsellem – Piper Sandler & Co., Research Division
Ashwani Verma – UBS Investment Bank, Research Division
Glen Santangelo – Barclays Bank PLC, Research Division
Matthew Dellatorre – Goldman Sachs Group, Inc., Research Division
Presentation
Operator
Hello everybody, and welcome to the Q2 2026 Teva Pharmaceutical Industries Earnings Conference Call. My name is Elliot. I’ll be coordinating your call today. [Operator Instructions] I would now like to hand over to Christopher Stevo.
Christopher Stevo
Senior Vice President of Investor Relations & Competitive Intelligence
Thank you, Elliot. Good morning and good afternoon, everyone. Thank you for joining us on our second quarter call. Obviously, our materials are posted to our website this morning, so please see those. And before I turn the call over to our CEO, Richard Francis, I’d like to remind everyone that we’ll be making forward-looking statements on this call. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance.
Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. These factors are described in our earnings press release and our most recent Forms 10-Q and 10-K filed with the SEC. Any statements that we make are only as of today, we undertake no obligation to update these
